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Purpose: Posterior capsular opacification (PCO) is a common long-term complication of modern cataract surgery. We
have shown that Zebularine, an inhibitor of DNA methylation, suppresses transforming growth factor-β (TGFβ)-induced
lens epithelial cells (LECs)–myofibroblasts transdifferentiation. The purpose of this study is to evaluate the role that
Zebularine plays in the inhibition of PCO pathogenesis, including its effect on attachment, migration, and proliferation
of LECs in vitro.
Methods: A tetrazolium dye–reduction assay (MTT test) was performed to determine cell proliferation. Cell attachment
was assessed by modified MTT test. Migration was determined by the transwell method after incubation of LECs with
Zebularine. The effect of Zebularine on DNA-methyltransferase 1 (DNMT1), phospho-p44/42 Map Kinase, and protein
kinase B (Akt) were analyzed by western blot.
Results: Zebularine was an effective inhibitor of human LEC proliferation, attachment, and migration in vitro. A
Zebularine concentration of 100 μM accounted for the following: inhibition of cell proliferation of 57.2%, reduction in
cell attachment to 29.6%, and inhibition of cell migration of 58.9%. All effects were dose dependent. Zebularine treatment
resulted in dose-dependent decreases of DNMT1, phosphorylated p44/42 MAP Kinase, and phosphorylated Akt.
Conclusions: Zebularine is capable of inhibiting the crucial cellular events in PCO pathogenesis in vitro. Zebularine acts
through the inhibition of DNMT1, and it consequently down regulation of the expression of proliferative and survival
genes that relate to pathogenesis of PCO. These findings suggest that Zebularine may become a therapeutic approach for
the prevention of PCO.
The  continuous  improvements  in  surgical  technique,
intraocular  lens  (IOL)  design,  and  IOL  material  have
significantly  reduced  the  incidence  of  posterior  capsule
opacification (PCO) in the past 30 years [1]. However, PCO
remains the most common long-term complication of modern
cataract surgery [2,3]. Decreased visual acuity induced by
PCO is reported to occur in 20% to 40% of patients 2 to 5
years after surgery [3,4]. As a routine treatment for PCO,
neodymium: YAG (Nd:YAG) laser capsulotomy is performed
successfully  in  many  patients.  However,  there  are
complications  such  as  retinal  detachment,  damage  to  the
intraocular lens, and cystoid macular edema [5,6].
Cataract surgery induces a wound-healing response in the
lens, and residual lens epithelial cells (LECs) undergo an
epithelial-to-mesenchymal  transition  (EMT),  followed  by
enhanced proliferation, migration, and collagen deposition.
Therefore,  postsurgical  medical  inhibition  of  LECs  EMT,
proliferation, and migration is a possible option for preventing
PCO.
Epigenetic  modifications  are  post-transcriptional,
reversible  events  that  do  not  target  gene  sequence,  and
inhibition  of  these  mechanisms  could  theoretically  be
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advantageous in the treatment of fibrosis disease [7,8]. As a
consequence, the role of epigenetic regulators like histone
deacetylase (HDAC) and DNA methyltransferase (DNMT)
inhibitors as a treatment for PCO is under evaluation.
Zebularine  is  a  cytidine  analog  containing  a  2-(1H)-
pyrimidinone ring that was originally developed as a cytidine
deaminase inhibitor. It acts primarily as a trap for DNMT
protein by forming tight covalent complexes between DNMT
protein and Zebularine-substituted DNA [9]. In contrast to
other DNMT inhibitors, it is quite stable [10,11] and low
toxicity [12-14]. Preclinical studies using Zebularine have
shown favorable toxicity and stability profiles, making it an
attractive candidate for epigenetic treatment of PCO [13].
The  purpose  of  this  study  was  to  determine  whether
Zebularine is capable of inhibiting the crucial cellular events
for  PCO  formation  (i.e.,  human  LEC  proliferation,
attachment, and migration) in vitro.
METHODS
The institutional review board (IRB) of Fudan University Eye
and  ENT  Hospital,  Shanghai,  China  approved  our  use  of
cultured  human  LECs.  All  procedures  conformed  to  the
Declaration  of  Helsinki  for  research  involving  human
subjects. The Zebularine we used was a kind gift from Dr.
Victor  E.  Marquez  (Laboratory  of  Medicinal  Chemistry,
National Cancer Institute, Frederick, MD).
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22Cell culture: HLE B-3 cells, an immortalized cell line
derived from infant human lens tissue and transformed with
adenovirus  12-simian  virus  (SV40),  were  obtained  from
ATCC (Rockville, MD) and cultured in Eagle’s minimum
essential medium (GIBCO BRL, Grand Island, NY) with 20%
fetal bovine serum, 100 units/ml penicillin, and 100 mg/ml
streptomycin at 37 °C in a humidified 5% CO2 atmosphere.
Cell proliferation assay: HLE B-3 cells were seeded in
96-well plates (150 μl/well at a density of 5×103 cells/well in
DMEM containing 10% FBS). After 24 h, Zebularine (10, 50,
and 100 μM) was added. After another 12, 24, 48, 72, and 96
h, cells were washed gently twice with PBS, and fresh medium
(150  μl)  was  added  to  each  well  with  MTT  (3-(4,  5-
dimethyl-2-thiazolyl)-2, 5-diphenyl-2H tetrazolium bromide,
5mg/ml, 20 µl; Sigma, St. Louis, MO). After 4 h of incubation,
the supernatants were decanted, and the formazan precipitates
were solubilized by the addition of 150 µl of 100% DMSO
(Sigma) and placed on a plate shaker for 10 min. Absorbance
at  550  nm  was  determined  on  a  multi-well  plate  reader
(Benchmark plus™; Bio-Rad, Tokyo, Japan). The number of
proliferated cells was proportional to the absorbance of MTT
at 550 nm. All experiments were performed at least three
times.
Cell  attachment  assay:  The  attachment  assay  was
performed by a modified MTT assay using 96-well plates
coated with fibronectin. After treatment with Zebularine (10,
50, and 100 μM) for 48 h, LECs were trypsinized and re-
suspended  in  DMEM  with  0.4%  FBS.  One  hundred
microliters of cell suspension (104 cells) were added to each
well and allowed to attach for 5 and 15 min. The cells were
washed gently twice with PBS, and fresh medium (150 µl)
was added to each well with MTT (5 mg/ml, 20 µl; Sigma).
After 4 h of incubation, the supernatants were decanted, and
the formazan precipitates were solubilized by the addition of
150 µl of 100% DMSO (Sigma) and placed on a plate shaker
for 10 min. Absorbance at 550 nm was determined on a multi-
well plate reader (Benchmark plus™; Bio-Rad). The number
of attached cells was proportional to the absorbance of MTT
at 550 nm. All experiments were performed at least three
times.
Cell  migration  assay:  Migration  was  measured  using
Transwell  (Costar,  Cambridge,  MA)  assay,  as  previously
described [15]. Briefly, 5×104 LECs were seeded in the upper
part  of  a  chamber  in  24-well  plates  after  treatment  with
Zebularine (10, 50, and 100 μM) for 48 h, with inserts coated
with fibronectin (2 µg/cm2). The lower chamber was filled
with 0.4% FBS-DMEM containing 20nng/ml recombinant
PDGF (R&D Systems Inc., Minneapolis, MN). After 5 h
incubation, the inserts were washed three times with PBS,
fixed with cold methanol (4 °C) for 10 min, and counterstained
with hematoxylin for 20 min. The number of migrated cells
was  counted  by  phase-contrast  microscopy  (200×).  Three
randomly  chosen  fields  were  counted  per  insert.  All
experiments were performed at least three times.
Western  blot  assay:  Confluent  cells  grown  in  6-well
plates in DMEM with 0.4% FBS were lysed, supernatants
were collected, and proteins were resolved on Tris-HCl 10%
polyacrylamide gels at 120 V. The proteins were transferred
to PVDF blotting membrane (Millipore, Bedford, MA). The
membranes  were  probed  with  antibodies  for  DNA-
methyltransferase  1  (DNMT1;  Abcam,  Cambridge,  MA),
phospho-p44/42  MAP  Kinase  (Thr  202/Thy  204;  Cell
Figure  1.  Zebularine  inhibited  LECs
proliferation  in  a  dose-  and  time-
dependent  manner.  The  human  LECs
were  treated  with  various
concentrations  of  Zebularine  and  the
percentage  of  surviving  cells  was
determined by MTT assay from 12 to 96
h. A time- and dose-dependent decrease
in  proliferation  was  seen  with  the
application of Zebularine (10, 50, and
100  μM;  p<0.01).  A  Zebularine
concentration of 100 μM accounted for
the  inhibition  of  cell  proliferation  of
57.2% in 96 h.
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23Signaling,  Danvers,  MA),  phospho-AKT  (Ser  473;  Cell
Signaling), and glyceraldehyde 3-phosphate dehydrogenase
(GAPDH)  (Abcam),  respectively,  all  at  1:1,000  dilution.
Membranes were washed and incubated with a horseradish
peroxidase (HRP)-conjugated secondary antibody (1:3,000;
Vector Laboratories, Burlingame, CA) for 30 min at room
temperature.  Images  were  developed  using  ECL
chemiluminescence  detection  solution  (Amersham
Pharmacia Biotech, Cleveland, OH). All experiments were
performed at least three times.
Statistics: The data were analyzed using Student’s t-test,
and a p<0.05 was accepted as significant.
RESULTS
Zebularine inhibited LECs proliferation in a dose- and time-
dependent  manner:  The  human  LECs  were  treated  with
various concentrations of Zebularine, and the percentage of
surviving cells was determined by MTT assay from 12 to 96
h. A time- and dose-dependent decrease in proliferation was
seen with the application of Zebularine (10, 50, and 100 μM;
p<0.01). As shown in Figure 1, 25.6±4.1% inhibition of cells
occurred with 10 μM Zebularine at 96 h, 52.6±2.3% inhibition
with  50  μM  Zebularine,  and  57.2±3.3%  inhibition  with
100 μM Zebularine.
Zebularine decreased LECs attachment: LECs attachment
was measured using modified MTT test (Figure 2). After 48
h exposure to Zebularine, no statically significant difference
was found in LECs attachment between control and low-dose
Zebularine (10 μM)-treated cells. However, a dose-dependent
decrease in attachment was seen with the application of higher
concentrations of Zebularine (50 μM and 100 μM; p<0.01).
LECs attachment was significantly reduced by 70.4±5.3% in
the early phase (5 min) of cell attachment (p<0.01).
Zebularine inhibited LECs migration: LECs migration to the
lower compartment of a transwell was significantly increased
in response to PDGF stimulation (Figure 3). PDGF-induced
LECs migration was inhibited by Zebularine (50 and 100 μM)
in  a  dose-dependent  manner.  The  maximal  inhibition
(58.9±6.1%) was seen at 100 μM Zebularine (p<0.01).
Zebularine  inhibited  the  epigenetic  regulator:  Because  of
Zebularine’s activity as a DNMT inhibitor in other model
systems, its effect on expression of DNMT1 in LECs was
examined. As expected, Zebularine treatment was associated
with a dose-dependent depletion of DNMT1 in all three doses
(10, 50, and 100 μM; Figure 4).
Zebularine  inhibited  the  cellular  survival  genes:  Akt  is
involved in cellular survival pathways and is active after being
phosphorylated  at  serine  473.  In  this  study,  Zebularine
inhibited Akt phosphorylation at serine 473 in all three doses.
Mitogen-activated  protein  kinases  (MAPKs)  are  a  widely
conserved family of serine/threonine protein kinases involved
in  many  cellular  programs  such  as  cell  proliferation,
differentiation,  motility,  and  death.  The  p44/42  MAPK
signaling pathway can be activated in response to a diverse
range  of  extracellular  stimuli  including  mitogens,  growth
Figure  2.  Zebularine  decreased  LECs
attachment in a dose-dependent manner.
LECs attachment was measured using
modified MTT test. A dose-dependent
decrease in attachment was seen with
the application of high concentrations of
Zebularine (50 μM and 100 μM). LECs
attachment was significantly reduced to
29.6% in the early phase (5 min) of cell
attachment. *p<0.01, Error bar indicates
mean±SEM.
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24factors, and cytokines. In this study, phosphorylated p44/42
MAPK level decreased by 87.5% after treatment with high
dose (100 μM) Zebularine for 48 h (Figure 4).
DISCUSSION
In this study, we found that Zebularine is capable of inhibiting
the crucial cellular events in PCO pathogenesis in vitro. After
a  single  exposure  to  Zebularine  added  to  the  cell-culture
medium  in  the  presence  of  serum,  HLE-B3  proliferation,
attachment, and migration were effectively inhibited.
The initial cellular events in PCO can be described as the
migration and attachment of LECs to the posterior capsule
surfaces  and  their  following  proliferation.  In  this  study,
Zebularine  effectively  inhibited  LECs  attachment  and
migration. Inhibition of the initial stages in PCO development
may  prevent  the  disease  from  progressing  to  the  more
advanced stages commonly associated with a severe reduction
in visual acuity.
The effect of Zebularine on cell migration was reported
by  Hellebrekers  et  al.  [16].  However,  they  reported  that
migration of endothelial cells was not significantly influenced
by treatment with Zebularine at concentrations up to 500 μM.
This difference may be due to different type of cells and
methods used in different experiments. Hellebrekers et al.
[16] used human umbilical vein endothelial cells (HUVEC)
and  scratched  wound  assay  in  response  to  Zebularine
treatment, while we used fetal LECs and transwell assay.
Hellebrekers’s method more likely showed a wound healing
response, while the transwell assay method showed the effect
of Zebularine on LECs chemotaxis response. In addition, the
pretreatment with Zebularine was 48 h in our experiment,
while Hellebrekers et al. [16] pretreated the cells for 72 h.
Proliferation  is  another  important  event  in  the
pathogenesis of PCO. Our results demonstrate that Zebularine
effectively inhibited LECs proliferation in a time- and dose-
dependent manner. Previous studies showed that Zebularine
Figure  3.  Zebularine  inhibited  LECs
migration in a dose-dependent manner.
LECs  migration  to  the  lower
compartment  of  a  transwell  was
significantly  increased  in  response  to
PDGF  stimulation.  PDGF-induced
LECs  migration  was  inhibited  by
Zebularine  (A)  in  a  dose-dependent
manner  (B).  The  maximal  inhibition
(58.9±6.1%)  was  seen  at  100  μM
Zebularine (p<0.01). *p<0.01, Error bar
indicates mean±SEM.
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25induces apoptotic cell death in many cell lines. Scott et al.
[13] analyzed the effects of Zebularine on cell proliferation in
acute myeloid leukemia cells (AML193 cell line) using MTT
and tritiatedthymidine assays. They found that treatment of
AML193 cells with Zebularine concentrations necessary to
demethylate  DNA  causes  a  decrease  in  cell  viability  and
proliferation, and an increase in the percentage of apoptotic
cells and cells arrested in G2/M of the cell cycle.
Calvisi  et  al.  [17]  reported  that  treatment  with  the
demethylating agent Zebularine caused marked activation of
MST1, p38MAPK, and JNK in hepatoma cell lines. Neureiter
et al. [14] found that higher concentrations of Zebularine led
to  rapid  induction  of  apoptosis  in  YAP  C,  DAN  G,  and
Panc-89  pancreatic  adenocarcinoma  cells;  lower
concentrations remained ineffective in these cell lines. Billam
et al. [18] found that Zebularine inhibits human breast cancer
cell growth in a dose- and time-dependent manner.
Pharmacologic  PCO  prevention  represents  a  valuable
option, especially for refractive and pediatric cataract surgery.
The  current  therapeutic  concepts  for  pharmacologic  PCO
prevention are compromised in terms of potential clinical
application. The effective agents, represented by mitomycin-
C  [19]  and  5-fluorouracil  [20],  require  a  sealed-capsule
irrigation device due to significant toxic side effects [21].
Methylation inhibitor is a new strategy for treating disease.
Methylation inhibitor is well tolerated and safe, according to
a recent phase I clinical studies [22-24]. Further phase II
clinical  trials  are  undergoing.  Other  DNA  methylation
inhibitors,  such  as  5-Aza-C  and  5-Aza-dC,  have  shown
significant  clinical  activity  against  tumors.  However,  the
clinical use of these agents is complicated by their toxicity and
instability  in  aqueous  solutions  [13].  The  half-life  of
Zebularine is much longer, and its toxicity is much lower.
Therefore,  Zebularine  offers  a  better  option  for  potential
clinical application.
We  have  shown  that  Zebularine  suppressed  TGFβ2-
induced  lens  epithelial  cell–myofibroblast
transdifferentiation [7]. In this study, our data demonstrate
that  Zebularine  is  an  effective  demethylating  agent.
Zebularine can inhibit LECs proliferation, attachment, and
Figure 4. The effect of Zebularine on the
expression of methylation related genes
and genes involved in the pathogenesis
of  PCO.  Zebularine  treatment  was
associated  with  a  dose-dependent
depletion of DNMT1 in all three doses
(10,  50,  and  100  μM).  Zebularine
inhibited the phosphorylation of Akt at
serine  473.  Phosphorylated  p44/42
MAPK level decreased by 87.5% after
treatment  with  high  dose  (100  μM)
Zebularine in 48 h.
Figure  5.  Model  for  Zebularine
inhibiting  PCO.  We  have  shown  that
Zebularine  inhibited  MeCP2,  and
furthermore, inhibits TGFβ-induced α-
SMA expression. In this study, we found
that Zebularine is capable of inhibiting
the  crucial  cellular  events  in  PCO
pathogenesis,  including  LECs
proliferation,  attachment,  and
migration. Therefore, Zebularine could
potentially  prevent  PCO  formation.
LECs: lens epithelial cells; IOL: intra
ocular lens.
Molecular Vision 2012; 18:22-28 <http://www.molvis.org/molvis/v18/a4> © 2012 Molecular Vision
26migration in vitro. These findings suggest that Zebularine may
become a new option for preventing PCO after conventional
cataract surgery (Figure 5).
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